Patent References
2868691
2885427
3014844
3219533
3320125
3809294
3897779
Steroidal aerosol compositions and process for the preparation thereof Patent #: 4044126
Aerosol propellant compositions Patent #: 4174295
Process for the preparation of a mixture of an anti-inflammatory steroid and a fluoro-chloro-hydrocarbon to be used as a propellant Patent #: 4347236
More ...
Composition for treating asthma Patent #: 4405598
Drug-containing chlorofluorocarbon aerosol propellent formulations Patent #: 4814161
5118494
Aerosol drug formulations Patent #: 5126123
Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content Patent #: 5182097
Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content Patent #: 5190029
Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants Patent #: 5202110
Medicinal aerosol formulations Patent #: 5225183
Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations Patent #: 5230884
Method for preparing medicinal aerosol formulation containing coated medicament Patent #: 5348730
Non-chlorofluorocarbon aerosol formulations Patent #: 5474759
Aerosol formulations containing propellant 134a and fluticasone propionate Patent #: 5658549
Aerosol formulations containing P134a and salbutamol Patent #: 5674471
Medicinal aerosol formulations Patent #: 5674473
Medicinal aerosol formulations Patent #: 5681545
Medicinal aerosol formulations Patent #: 5683677
Medicinal aerosol formulations Patent #: 5695743
Inventors
Assignee
Application No. 453820 filed on 05/30/1995
US Classes: 424/45 ,
Organic pressurized fluid 424/46 Powder or dust containing
Examiners Primary:
Bawa, Raj
Attorney, Agent or Firm
Foreign Patent References 134923 DK. 02/13/1977 0 372 777 EP. 06/13/1990 A-0 372 777 EP. 06/13/1990 A-0 504 112 EP. 09/13/1992 0 504 112 EP. 09/13/1992 27 03 119 DE. 10/13/1990 437766 SE. 03/13/1985 86/04233 WO. 07/13/1986 A-86 04233 WO. 07/13/1986 90/07333 WO. 07/13/1990 91/04011 WO. 04/13/1991 91/11495 WO. 08/13/1991 91/11496 WO. 08/13/1991 91/11173 WO. 08/13/1991 91/14422 WO. 10/13/1991 92/00107 WO. 01/13/1992 92/06675 WO. 04/13/1992 92/08446 WO. 05/13/1992 92/08447 WO. 05/13/1992 A-92 08446 WO. 05/13/1992 92/11190 WO. 07/13/1992 92/22287 WO. 12/13/1992 92/22288 WO. 12/13/1992 93/11744 WO. 06/13/1993 93/11747 WO. 06/13/1993 93/11745 WO. 06/13/1993 93/11743 WO. 06/13/1993
International Class A61K 009/12
Foreign Application Priority Data 1991-12-12 GB
Abstract This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
Other References Oberholz, Frankfurter Allgemeine Zeitung, Oct. 1989, vol. 25, No. 207, p. 7 Dalby et al., Pharmaceutical Technology, Mar. 1990, vol. 14, No. 3, pp. 26-33 Amzacort™ carton, William H. Rorer, Inc., Fort Washington, Pennsylvania, USA 19034, 1986 Pharmaceutical Journal, Sep. 29, 1990, vol. 245, pp. 428-429, The Theory and Practice of Industrial Pharmacy, 2nd Ed., 1976 (Philadelphia, PA: Lea and Febiger), pp. 270 and 276-278 Handbook of Aerosol Technology, 2nd Edition, 1979 (New York, New York: Van Nostrand Reinhold Company), pp. 30, 32, 33, 166, 167, 232, 233 U.S. Senate Hearings, 12-14 May 1987, 343-347, 437 (U.S. Government Printing Office, Washington, D.C., 1987), CIS:1987-S321-26 Hagers Handbook of Pharmaceutical Practice, 1971, pp. 342-354 (Berlin: Spring-Verlag
May 30, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
